Jeremiah Harnett

This inventor holds 29 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.), Ipsen Pharma S.a.s., Britannia Pharmaceuticals Limited. Active years: 2002-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeremiah Harnett. Retrieved from https://idiyas.com/inventor/jeremiah-harnett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 5)

% Patents Active = 24.1

CIPO Patents = 3

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 207(Granted Patents)

Company Filing History:

18 out of 119

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Britannia Pharmaceuticals Limited

Societe De Conseils De Recherches Et D'applications (s.c.r.a.s.)

patents

6. 1 out of 73

Societe De Conseils De Recherches Et D'applications Scientifiques

patents

7. 1 out of 834,453

Other

patents

Years Active: 2002-2023

Loading Chart...

Areas of Expertise:

Therapeutical Composition

Apomorphine

Clay Compositions

Sustained-Release

Peptides

Heterocycles

Medicaments

Lipoic Acid

Amino Acid Derivatives

Amidine Derivatives

Pharmaceutical Compositions

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11766431 - Therapeutical composition containing apomorphine as active ingredient (2023-09-26),

2. 11026938 - Therapeutical composition containing apomorphine as active ingredient (2021-06-08),

3. 9511023 - Clay compositions (2016-12-06),

4. 9415012 - Sustained-release composition containing peptides as active ingredient (2016-08-16),

5. 8288560 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments (2012-10-16),

6. 7956075 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments (2011-06-07),

7. 7576241 - Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2009-08-18),

8. 7553976 - Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2009-06-30),

9. 7473779 - Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2009-01-06),

10. 7459558 - Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2008-12-02),

11. 7345066 - Use of thiazole derivatives for preparing a medicine for protecting mitochondria (2008-03-18),

12. 7285664 - Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments (2007-10-23),

13. 7186752 - Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2007-03-06),

14. 7122535 - Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2006-10-17),

15. 7019025 - Derivatives of amidines, their preparation and their use as medicaments (2006-03-28),

Title: **Jeremiah Harnett: Innovator in Pharmaceutical Composition**

Introduction

Jeremiah Harnett is a highly regarded inventor based in Gif-sur-Yvette, France. With an impressive portfolio of 29 patents, he has made significant contributions to the field of pharmaceutical sciences. His work primarily focuses on therapeutic compositions that aim to improve the treatment of various medical conditions, including Parkinson's disease.

Latest Patents

Among his latest innovations is a therapeutic composition containing apomorphine as the active pharmaceutical ingredient. This formulation incorporates a water-miscible co-solvent, an antioxidant, and water, creating a solution with a pH greater than 4. The composition is specifically designed for parenteral administration, making it suitable for the treatment of Parkinson's disease. The manufacturing process for this pharmaceutical composition involves weighing the apomorphine and introducing it into a container with the co-solvent and antioxidant under agitation until complete dissolution occurs.

Career Highlights

Jeremiah has had a notable career, contributing his expertise at several esteemed organizations. He has worked for Société de Conseils de Recherches et d'Applications Scientifiques (SCRAS) and Ipsen Pharma S.A.S., where he has further advanced pharmaceutical research and development.

Collaborations

Throughout his career, Jeremiah has collaborated with distinguished professionals in the field. Notable coworkers include Serge Auvin and Dennis Bigg, both of whom have contributed to the advancement of pharmaceutical innovations alongside him.

Conclusion

Jeremiah Harnett's work exemplifies the spirit of innovation in pharmaceuticals. With his extensive patent portfolio and impactful collaborations, he continues to pave the way for advancements that enhance therapeutic options for patients with Parkinson's disease and beyond. His contributions to the field of medicine highlight the importance of innovative thinking and dedicated research in developing effective treatments.

Profile summary based on public USPTO records.